Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes by Swoboda, P.P. et al.
This is a repository copy of Cardiovascular magnetic resonance measures of aortic 
stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control 
and clinical outcomes.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/144027/
Version: Published Version
Article:
Swoboda, P.P., Erhayiem, B., Kan, R. et al. (10 more authors) (2018) Cardiovascular 
magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 
diabetes: association with glycaemic control and clinical outcomes. Cardiovascular 
Diabetology, 17. 35. ISSN 1475-2840 
https://doi.org/10.1186/s12933-018-0681-4
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Swoboda et al. Cardiovasc Diabetol  (2018) 17:35 
https://doi.org/10.1186/s12933-018-0681-4
ORIGINAL INVESTIGATION
Cardiovascular magnetic resonance 
measures of aortic stiffness in asymptomatic 
patients with type 2 diabetes: association 
with glycaemic control and clinical outcomes
Peter P. Swoboda1* , Bara Erhayiem1, Rachel Kan1, Adam K. McDiarmid1, Pankaj Garg1, Tarique A. Musa1, 
Laura E. Dobson1, Klaus K. Witte1, Mark T. Kearney1, Julian H. Barth2, Ramzi Ajjan1, John P. Greenwood1 
and Sven Plein1
Abstract 
Background: We aimed to investigate in patients with type 2 diabetes whether aortic stiffness is: (i) associated with 
glycaemic control, (ii) associated with adverse outcomes and (iii) can be reversed on treatment with RAAS inhibition.
Methods: Patients with type 2 diabetes (N = 94) and low vascular risk underwent assessment of cardiovascular risk 
and CMR assessment of ascending aortic distensibility (AAD), descending aortic distensibility (DAD) and aortic pulse 
wave velocity (PWV). Of these patients a subgroup with recent onset microalbuminuria (N = 25) were treated with 
renin–angiotensin–aldosterone system (RAAS) inhibition and imaging repeated after 1 year. All 94 patients were fol-
lowed up for 2.4 years for major adverse cardiovascular disease (CVD) events including myocardial infarction detected 
on late gadolinium enhancement CMR.
Results: Ascending aortic distensibility, DAD and PWV all had a significant association with age and 24 h systolic 
blood pressure but only AAD had a significant association with glycaemic control, measured as HbA1c (Beta − 0.016, 
P = 0.04). The association between HbA1c and AAD persisted even after correction for age and hypertension. CVD 
events occurred in 19/94 patients. AAD, but not DAD or PWV, was associated with CVD events (hazard ratio 0.49, 95% 
confidence interval 0.25–0.95, P = 0.01). On treatment with RAAS inhibition, AAD, but not DAD or PWV, showed signifi-
cant improvement from 1.51 ± 1.15 to 1.97 ± 1.07  10−3 mmHg−1, P = 0.007.
Conclusions: Ascending aortic distensibility measured by CMR is independently associated with poor glycaemic 
control and adverse cardiovascular events. Furthermore it may be reversible on treatment with RAAS inhibition. AAD 
is a promising marker of cardiovascular risk in asymptomatic patients with type 2 diabetes and has potential use as a 
surrogate cardiovascular endpoint in studies of novel hypoglycaemic agents.
Clinical trials registration https://clinicaltrials.gov/ct2/show/NCT01970319
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Introduction
With aging there is progressive stifening of the aorta that 
appears to be accelerated by the presence of additional 
risk factors such as hypertension and diabetes [1]. Aortic 
stifness can be assessed by cardiovascular magnetic res-
onance (CMR) either directly as aortic distensibility (AD) 
the relative change in aortic cross sectional area divide 
by pulse pressure; or indirectly as pulse wave veloc-
ity (PWV) the propagation speed of the velocity wave 
between two aortic locations. PWV is proportional to the 
square root AD by the Bramwell-Hill equation [2]. hese 
techniques do not expose the patient to ionising radia-
tion or contrast agent and can image three dimensional 
aortic characteristics at any point along the vessel [3].
Increased aortic stifness can be detected in patients 
with type 2 diabetes with and without established cardio-
vascular disease by CMR [4–6] and applanation tonom-
etry [7–10]. Although CMR measures of aortic stifness 
have been shown to predict vascular morbidity [11, 12] 
studies speciic to the diabetic population have not yet 
been conducted.
Patients with diabetes and microalbuminuria have even 
further elevated cardiovascular risk [13, 14]. Data from 
clinical trials suggests that the use of renin–angioten-
sin–aldosterone system (RAAS) inhibition in this patient 
group may reduce this risk [15, 16]. It has been shown 
that AD and PWV measured by CMR can be improved 
by RAAS inhibition in other high risk disease cohorts [17, 
18] but this principle is not yet been tested in diabetes.
We aimed to investigate in patients with type 2 diabe-
tes whether aortic stifness is: (i) associated with glycae-
mic control, (ii) associated with adverse outcomes and 
(iii) can be reversed on treatment with RAAS inhibition. 
We also aimed to compare three CMR measures of aortic 
stifness including ascending aortic distensibility (AAD), 
descending aortic distensibility (DAD) and aortic pulse 
wave velocity (PWV).
Methods
We measured aortic stifness by CMR in 94 asympto-
matic patients with type 2 diabetes from a cohort of 100 
patients with type 2 diabetes studied to investigate the 
relationship between microalbuminuria, cardiac remod-
elling and ibrosis (Fig. 1) [19, 20]. Patients were recruited 
from 30 primary care health centres in the local area 
between August 2013 and March 2015 [20]. Exclusion 
criteria for all subjects were known cardiac disease, kid-
ney disease (eGFR < 30  ml/min/1.73  m2), uncontrolled 
hypertension, treatment with insulin or angiotensin 
converting enzyme (ACE) inhibitor/angiotensin recep-
tor blocker (ARB). All patients underwent 24  h blood 
pressure (BP) monitoring with a Welch-Allyn 6100 
ambulatory blood pressure monitor. All HbA1c meas-
urements since diagnosis were recorded from review of 
records.
We speciically recruited patients with persistent 
microalbuminuria (N = 45) who were due to be started 
on an ACE inhibitor by their primary care team follow-
ing the baseline investigations [21]. ACE inhibitors were 
uptitrated to maximum tolerated dose and those who 
could not tolerate an ACE inhibitor because of cough 
were changed to an ARB. All testing was repeated after 
1  year treatment with RAAS inhibition. In addition 20 
age and sex matched healthy controls underwent identi-
cal CMR studies.
he study was approved by the National Research 
Ethics Service (13/YH/0098) and conducted in accord-
ance with the declaration of Helsinki. All subjects gave 
informed written consent.
CMR protocol
Patients and controls underwent CMR using an identi-
cal protocol on a dedicated cardiovascular 3 Tesla Philips 
Achieva system equipped with a 32 channel coil and 
 MultiTransmit® technology.
For aortic distensibility, brachial artery blood pressure 
was recorded by Dinamap (Critikon, Tampa, USA) imme-
diately prior to high temporal resolution multi-phase 
SSFP cine imaging (retrospective gating, slice thick-
ness 10  mm, acquired spatial resolution 1.2 × 1.2  mm, 
acquired temporal resolution 50 phases, repetition time 
2.6  ms, echo time 1.3  ms, breath-held, acquired trans-
verse to the ascending and descending thoracic aorta at 
the level of the pulmonary artery bifurcation) (Fig. 2) [4]. 
Aortic PWV was assessed using identical geometric plan-
ning with retrospectively gated, through-plane, phase-
contrast velocity encoded images (single slice, 10  mm 
thick, acquired spatial resolution 2.9 × 2.9 mm, acquired 
temporal resolution 50 phases, repetition time 4.7  ms, 
echo time 2.8 ms, typical FOV 320, and VENC 200 cm/s, 
breath-held).
Late gadolinium enhancement (LGE) imaging of the 
heart was carried out more than 6  min after contrast 
injection (0.15  mmol/kg Gadovist, Bayer Pharma) using 
inversion recovery-prepared T1-weighted echo. he 
optimal inversion time to null signal from normal myo-
cardium was determined using a Look-Locker approach 
(acquired spatial resolution 1.54 × 1.76  mm, TR 3.5  ms, 
TE 2.0  ms, lip angle  25°, breath-held) performed in 
10–12 short axis slices with further slices acquired in 
the vertical and horizontal long axis orientations, phase-
swapped or imaged in systole, if indicated based on LGE 
imaging obtained or wall-motion abnormality.
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Fig. 1 Flow chart of patient recruitment
Fig. 2 Associations of three measures of aortic stiffness in asymptomatic patients with type 2 diabetes
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CMR interpretation
Cardiovascular magnetic resonance data were assessed 
quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, 
Canada) blinded to glycaemic status. To derive the aortic 
distensibility of the ascending and descending thoracic 
aorta, cross sectional measurements were made by man-
ual planimetry of the endovascular-blood pool interface 
for each phase to determine the maximal and minimal 
aortic dimensions. Aortic distensibility  (mmHg−1) was 
calculated using the equation:
Aortic PWV (m/s) was calculated by dividing the dis-
tance separating two locations and the transit time 
needed to cover this distance [22]. Analysis was per-
formed using a validated software (PMI v0.4, https://
github.com/plaresmedima/PMI-0.4-Runtime-CMR-
Leeds) based on IDL 6.4 (ITT Visual Information Sys-
tems, Boulder, USA) [23]. he distance between the 
ascending and descending aorta was measured manually 
from the sagittal/oblique cines of the aortic arch. Tran-
sit time was calculated using the foot–foot delay method 
from velocity encoded images of the ascending and 
descending aorta, manually contoured to derive velocity–
time curves [24].
he presence of silent MI was identiied by two physi-
cians experienced (5 and 15 years) in CMR interpretation 
based upon typical subendocardial distribution of LGE 
present.
Laboratory methods
Cholesterol, hsCRP and microalbumin were measured on 
Siemens Advia (Siemens Healthcare Diagnostics, Cam-
berley, UK) with typical coeicient of variability (CV) 
0.94, 3.7 and 2.2%, respectively. HbA1c was measured on 
Tosoh G8 (Tosoh Bioscience, Tessenderlo, Belgium) with 
typical CV 1.4%. Serum aldosterone was measured in 
the SAS Steroid Centre (Leeds Teaching Hospitals) with 
an in-house radio-immunoassay with typical CV 11% at 
218 pmol/L.
Follow up
Patients were followed up by review of electronic and 
clinical records for CVD events including cardiovascu-
lar death, myocardial infarction (either silent detected on 
LGE CMR or clinically recognised during the follow up 
period), stroke, heart failure or arrhythmia.
Statistical analysis
Statistical analysis was performed using IBM  SPSS® 
Statistics 22.0 (IBM Corp., Armonk, NY). Continuous 
Aortic distensibility = � aortic area/(pulse pressure
× minimum aortic area).
variables were expressed as mean ± SD. Categorical vari-
ables were expressed as N (%). Logistic regression was 
performed to identify clinical and aortic parameters 
associated with CVD events over follow up. Univariable 
linear regression was performed to identify associations 
between clinical parameters and AAD, DAD and PWV. 
Only factors with a signiicant association on univariable 
regression (P < 0.05) were included in multivariable lin-
ear regression. In those who underwent treatment with 
RAAS inhibition paired t tests were used to compare 
parameters before and after treatment. When normally 
distributed, data are presented as mean ± SD. P < 0.05 
was considered statistically signiicant.
Results
Ninety-four patients had a CMR protocol that included 
aortic imaging and were included in this study. Patients 
had a mean age of 61 ± 11 years (range 32–86), Table 1. 
81% of participants were male with mean duration of 
diabetes of 5 ± 5 years and HbA1c of 62 ± 16 mmol/mol. 
he majority were on metformin therapy (88%) with 34% 
receiving, a sulphonylurea 34, 10% a gliptin and only 4% 
took another hypoglycaemic agent (exanatide, pioglita-
zone, dapaglilozin and repaglinide, in one patient each). 
On 24  h ambulatory monitoring, blood pressure was 
well controlled at 131 ± 15/72 ± 9  mmHg. Only 13% of 
patients were taking an antihypertensive which included 
a calcium channel blocker 11%, a diuretic 4% and a beta 
blocker 3%. Twenty age and sex matched healthy con-
trols were recruited with 7 (70%) male, mean age 56 ± 11, 
clinic blood pressure 127 ± 10/77 ± 9 mmHg and HbA1c 
of 38 ± 3 mmol/mol.
Baseline AAD was 1.81 ± 1.16  10−3 mmHg−1, DAD was 
2.11 ± 1.05  10−3 mmHg−1 and PWV was 8.00 ± 2.87 m/s. 
In healthy controls AAD was 2.78 ± 1.67  10−3 mmHg−1, 
DAD was 3.47 ± 1.54  10−3  mmHg−1 and PWV was 
7.58 ± 2.11  m/s. AAD and DAD were signiicantly 
lower in patients with diabetes than matched controls 
(P = 0.002 and 0.0002 respectively). he diference in 
PWV was not signiicant (P = 0.74).
Association between demographic and risk factors 
and aortic parameters
Ascending aortic distensibility had signiicant associa-
tions with age (Beta − 0.063, P < 0.0001), current HbA1c 
(Beta −  0.016, P = 0.04), maximum HbA1c since diag-
nosis (Beta −  0.011, P = 0.02), sulphonylurea use (Beta 
−  0.57, P = 0.02) and 24 h systolic blood pressure (Beta 
−  0.026, P = 0.001), Table  2. On multivariable linear 
regression associations with age, current HbA1c and 
24 h systolic BP remained signiicant: Age (Beta − 0.068, 
P < 0.0001), current HbA1c (Beta −  0.017, P = 0.007) 
and 24  h systolic BP (Beta −  0.014, P = 0.03). In this 
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regression model maximum HbA1c was of borderline 
signiicance (Beta − 0.0077, P = 0.05) but sulphonylurea 
use was no longer signiicant (Beta − 0.12, P = 0.53).
DAD had signiicant associations with age (Beta 
− 0.052, P < 0.0001) and 24 h systolic BP (Beta − 0.020, 
P = 0.004) but no indices related to diabetes. PWV had 
signiicant associations with age (Beta 0.11, P < 0.0001) 
and 24 h systolic BP (Beta 0.040, P = 0.04) but no indices 
related to diabetes.
Cardiovascular disease events
Patients were followed up for 882 ± 146 days. 19 patients 
(20%) had a CVD event including silent MI on baseline 
scan 15 (16%), stroke 3 (3%), cardiovascular death 2 (2%), 
ST elevation MI 2 (2%), silent MI on follow up scan 1 
(1%), percutaneous coronary intervention 2 (2%), heart 
failure 1 (1%) and arrhythmia 1 (1%). 9/19 subjects with 
CVD events were asymptomatic and were only detected 
on CMR. 1 patient died from non-cardiovascular causes 
(malignancy).
he diferences in aortic stifness between those with 
silent MI on baseline scan (N = 15) and without silent MI 
did not reach statistical signiicance (AAD 1.33 ± 0.89 vs 
1.90 ± 1.19  10−3 mmHg−1, P = 0.0.8; DAD 1.76 ± 1.13 vs 
2.18 ± 1.03  10−3  mmHg−1 P = 0.12; PWV 8.31 ± 2.14 vs 
7.94 ± 3.00 m/s).
On logistic regression of the aortic parameters only 
AAD had a signiicant association with CVD events; 
hazard ratio (HR) 0.49, 95% conidence interval (CI) 
0.25–0.95, P = 0.01, Table 3. he associations of DAD and 
PWV with CVD events were not signiicant (P = 0.19 and 
0.45 respectively). Smoking was the only individual risk 
Table 1 Baseline Characteristics presented as mean ± standard deviation for continuous or N (%) for categorical data
ACE angiotensin converting enzyme, CVD cardiovascular disease
a 24 h blood pressure in patients with diabetes mellitus, clinic blood pressure in controls
Diabetes mellitus Control P value
N 94 20
Age (years) 60.8 ± 11.1 57.2 ± 11.6 0.72
Male gender, n (%) 76 (81) 14 (70) 0.34
Body mass index, kg/m2 28.7 ± 4.3 – –
Duration of diabetes, years 5.1 ± 4.5 – –
HbA1c, mmol/mol 61.6 ± 15.6 37.1 ± 4.6 < 0.0001
Median HbA1c since diagnosis, mmol/mol 63.8 ± 15.2 – –
Maximum HbA1c since diagnosis, mmol/mol 85.0 ± 24.6 – –
Microalbuminuria, n (%) 45 (48) – –
Systolic BP,  mmHga 131.1 ± 15.2 127.8 ± 15.5 0.93
Diastolic BP,  mmHga 72.3 ± 9.0 76.9 ± 10.3 0.05
Total cholesterol, mmol/L 4.3 ± 1.1 5.2 ± 0.9 0.003
Smoking 15 (16) 0 –
Metformin 83 (88) 0 –
Sulphonylurea 32 (34) 0 –
Gliptin 10 (11) 0 –
Other hypoglycaemic 4 (4) 0 –
Insulin 0 0 –
ACE inhibitor 0 0 –
Beta blocker 3 (3) 0 –
Calcium channel blocker 10 (11) 1 (5) 0.44
Diuretic 4 (4) 0 –
Statin 66 (70) 3 (15) < 0.0001
Aspirin 16 (17) 2 (10) 0.43
Serum aldosterone, pmol/L 306.3 ± 18.8 – –
High sensitivity C reactive protein, mg/L 3.5 ± 5.5 – –
Ascending aortic distensibility,  10−3 mmHg−1 1.81 ± 1.16 2.78 ± 1.67 0.002
Descending aortic distensibility,  10−3 mmHg−1 2.11 ± 1.05 3.47 ± 1.54 0.0002
Pulse wave velocity, m/s 8.00 ± 2.87 7.58 ± 2.11 0.74
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factor to have a trend to association with CVD events 
(HR 3.38, 95% CI 1.03–11.15, P = 0.05).
Response of aortic stiffness to RAAS inhibition
25 patients with persistent microalbuminuria were 
treated with RAAS inhibition and had a repeat CMR 
365 ± 38  days after the initial scan. Prescribed RAAS 
inhibition included ramipril 19, losartan 3, perindo-
pril 1, candesartan 1, irbesartan 1 equivalent to a dose 
of ramipril 4.9 ± 3.1  mg. RAAS inhibition was associ-
ated with a non-signiicant decrease in blood pressure 
of 5 ± 16 mmHg in systolic and 3 ± 8 mmHg in diastolic 
blood pressures. Over follow up there was no signiicant 
change in weight (86.2 ± 11.1 to 86.7 ± 11.5 kg, P = 0.51) 
or HbA1c (60.1 ± 17.7 to 61.8 ± 14.7 mmol/mol, P = 0.57). 
Treatment with RAAS inhibition was associated with a 
signiicant increase in AAD of 0.47 ± 1.04  10−3 mmHg−1 
but no signiicant change in DAD or PWV (P = 0.92 and 
0.42 respectively). After treatment with RAAS inhibi-
tion AAD was increased but was still signiicantly lower 
than in healthy controls (1.97 ± 1.07  10−3  mmHg−1 vs 
2.78 ± 1.67  10−3 mmHg−1, P = 0.04) (Table 4).
Table 2 Linear regression of association between aortic stiffness and clinical factors with significant associations in italic
Significant associations in italics
Abbreviations as in Table 1
AAD DAD PWV
Beta 95% CI P value Beta 95% CI P value Beta 95% CI P value
Age − 0.063 − 0.080; − 0.046 < 0.0001 − 0.052 − 0.068; 0.036 < 0.0001 0.11 0.064; 0.16 < 0.0001
Male gender 0.13 − 0.47; 0.73 0.69 − 0.18 − 0.73; 0.36 0.50 0.11 − 1.39; 1.61 0.88
Body mass index 0.0042 − 0.051; 0.060 0.88 − 0.030 − 0.080; 0.020 0.24 − 0.30 − 0.17; 0.11 0.67
Duration of diabetes − 0.037 − 0.090; 0.016 0.17 − 0.040 − 0.090; 0.0050 0.08 0.087 − 0.044; 0.22 0.19
HbA1c − 0.016 − 0.031; − 0.00073 0.04 − 0.00037 − 0.014; 0.013 0.96 0.027 − 0.010; 0.065 0.15
Median HbA1c since diag-
nosis
− 0.013 − 0.029; 0.0026 0.10 0.00084 − 0.013; 0.015 0.91 0.019 − 0.020; 0.058 0.33
Maximum HbA1c since 
diagnosis
− 0.011 − 0.020; − 0.0014 0.02 − 0.0035 − 0.012; 0.0050 0.42 0.0083 − 0.016; 0.032 0.50
Microalbuminuria − 0.21 − 0.69; 0.26 0.37 − 0.21 − 0.64; 0.22 0.34 0.89 − 0.28; 2.06 0.13
24 h systolic BP − 0.026 − 0.040; − 0.011 0.001 − 0.020 − 0.034; − 0.0067 0.004 0.040 0.0014; 0.078 0.04
24 h diastolic BP − 0.0058 − 0.033; 0.021 0.67 − 0.0027 − 0.027; − 0.022 0.83 − 0.0015 − 0.068; 0.065 0.97
Total cholesterol 0.15 − 0.062; 0.36 0.16 0.056 − 0.14; 0.25 0.57 − 0.44 − 0.97; 0.081 0.10
Smoking 0.11 − 0.54; 0.76 0.74 0.098 − 0.49; 0.69 0.74 − 0.59 − 2.20; 1.02 0.47
Metformin 0.27 − 0.47; 1.01 0.47 0.35 − 0.31; 1.02 0.30 0.32 − 2.16; 1.51 0.73
Sulphonylurea − 0.57 − 1.06; − 0.08 0.02 0.34 − 0.79; 0.11 0.14 1.17 − 0.056; 2.39 0.06
Gliptin − 0.31 − 1.08; 0.46 0.43 0.14 − 0.57; 0.83 0.70 0.73 − 1.18; 2.64 0.45
Statin − 0.048 − 0.57; 0.47 0.86 − 0.13 − 0.60; 0.35 0.60 0.38 − 0.91; 1.67 0.56
Aspirin − 0.61 − 1.23; 0.012 0.06 − 0.51 − 1.08; − 0.51 0.07 1.10 − 0.46; 2.66 0.16
Table 3 Logistic regression of the association 
between aortic stiffness and clinical factors with CVD 
events
Significant associations in italics
CI confidence interval, AAD ascending aorta distensibility, DAD descending aorta 
distensibility, PWV pulse wave velocity, CVD cardiovascular disease
Hazard ratio 95% CI P value
AAD 0.49 (0.25; 0.95) 0.01
DAD 0.70 (0.41; 1.20) 0.19
PWV 1.07 (0.90; 1.26) 0.45
Age 1.05 (1.00; 1.10) 0.07
Gender 0.19 (0.02; 1.52) 0.12
Body mass index 0.97 (0.86; 1.09) 0.62
Duration of diabetes 0.99 (0.88; 1.10) 0.80
HbA1c 0.98 (0.95; 1.02) 0.35
Median HbA1c since diagnosis 1.01 (0.97; 1.04) 0.75
Maximum HbA1c since diagnosis 1.00 (0.97; 1.02) 0.74
Microalbuminuria 2.19 (0.77; 6.16) 0.13
24 h systolic BP 1.02 (0.99; 1.06) 0.18
24 h diastolic BP 1.01 (0.95; 1.06) 0.80
Total cholesterol 0.89 (0.56; 1.43) 0.64
Smoking 3.38 (1.03; 11.15) 0.05
Serum aldosterone 1.00 (0.99; 1.00) 0.33
High sensitivity C reactive protein 0.99 (0.90; 1.09) 0.87
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Discussion
We have demonstrated increased aortic stifness by CMR 
in asymptomatic patients with type 2 diabetes compared 
to healthy controls. We have also shown that AAD, DAD 
and PWV are signiicantly inluenced by age and 24  h 
systolic BP. However only AAD had an association with 
HbA1c, which remained signiicant after correction for 
age and BP. AAD had a signiicant association with CVD 
events over 2.4  years follow up. Furthermore, no other 
traditional cardiovascular risk factors or marker of gly-
caemic control had an association with CVD events. 
Finally, we have shown with RAAS inhibition that AAD 
improves towards that of healthy controls.
he indings that AAD is associated with glycaemic 
control, adverse CVD events and that it is improved on 
treatment suggest that AAD has a potential role as an 
imaging marker of cardiovascular risk in asymptomatic 
patients with type 2 diabetes, although the cost and avail-
ability of CMR may be prohibitive for routine clinical use.
AAD and glycaemia
In the present study AAD was the only parameter of 
aortic stifness to have a signiicant association with gly-
caemic control, independent of blood pressure. Previous 
studies have shown an association between dysglycae-
mia and PWV [25, 26] but previous CMR studies show-
ing that diabetes is associated with decreased AAD were 
either not powered to show an association with glycae-
mic control [4, 5, 27] or data on glycaemic agents and 
glycaemic control were not reported [6]. he association 
of AAD with sulphonylurea therapy is potentially inter-
esting as it may implicate hypoglycaemia in the observed 
changes in AAD. However, this relationship was not sig-
niicant after correction for HbA1c suggesting it is merely 
a marker of worse glycaemic control. Taken together, gly-
caemic control appears to inluence AAD and hence glu-
cose levels may play a direct role in stifening of the aorta. 
Preliminary data suggests that aortic stifness may be 
reduced by the sodium-glucose co-transporter-2 inhibi-
tor dapaglilozin [28] and larger studies are required to 
conirm whether this is mediated by glucose lowering or 
other mechanisms.
AAD and CVD events
In the present study decreasing AAD appeared to be a 
marker of cardiovascular disease events, independently 
of conventional risk factors. he association between 
AAD and outcome in patients with diabetes are in agree-
ment with previous studies demonstrating the prognostic 
importance of AAD measured by CMR in asymptomatic 
cohorts of patients of varied cardiovascular risk (includ-
ing a minority with diabetes). AAD was measured in 3675 
subjects from the Multi-Ethnic Study of Atherosclero-
sis study who were followed up for 8.5 years [11]. In this 
period decreased AAD was associated with increased all-
cause mortality and CVD events (myocardial infarction, 
stroke, cardiac arrest and cardiovascular death). his 
risk was independent of conventional risk factors. In the 
Dallas Heart Study, both AAD and PWV were measured 
using CMR in 2122 participants free from cardiovascu-
lar disease [12]. After correction for traditional risk fac-
tors AAD and PWV had weak associations with nonfatal 
cardiac events and nonfatal extra-cardiac events but not 
cardiovascular death.
he prognostic importance of aortic PWV has been 
extensively studied by applanation tonometry with clear 
evidence of an incremental beneit over traditional risk 
factors for the prediction of cardiovascular events [29]. 
his technique has been used speciically in patients with 
diabetes and has shown that PWV is increased in diabetes 
independently of BP and associated with increased mortal-
ity [30]. PWV was not associated with CVD events in the 
present study and may relect measurement of low in a 
shorter section of aorta (arch only in our study compared 
with carotid to distal abdominal aorta by tonometry) or sig-
niicantly worse temporal resolution than with tonometry.
Reversing AAD
A subgroup of 25 patients in the present study were 
treated with RAAS inhibition for newly diagnosed 
Table 4 Baseline characteristics and change in AAD, DAD 
and PWV after 1 year treatment with RAAS inhibition in 25 
subjects
Significant associations in italics
Abbreviations as in Table 1
Baseline Follow up P value
Age 64.2 ± 11.8
Male gender, N (%) 22 (88%)
Body mass index, kg/m2 29.1 ± 3.4
Duration of diabetes, years 5.2 ± 4.5
HbA1c, % 7.6 ± 1.5
HbA1c, mmol/mol 60.1 ± 17.7
Median HbA1c since diagnosis, 
mmol/mol
63.4 ± 17.6
Maximum HbA1c since diagno-
sis, mmol/mol
86.6 ± 25.6
24 h systolic BP, mmHg 136.7 ± 19.3 131.6 ± 20.9 0.12
24 h diastolic BP, mmHg 72.9 ± 10.1 70.7 ± 11.1 0.07
Total cholesterol, mmol/L 4.1 ± 1.0
Smoking, N (%) 4 (16%)
Serum aldosterone, pmol/L 337.0 ± 190.8 238.8 ± 138.2 0.11
AAD  (10−3 mmHg−1) 1.51 ± 1.15 1.97 ± 1.07 0.007
DAD  (10−3 mmHg−1) 1.98 ± 1.29 1.96 ± 1.10 0.92
PWV (m/s) 8.95 ± 2.60 8.33 ± 3.58 0.42
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microalbuminuria. In these patients RAAS inhibition 
was associated with a signiicant increase in AAD (but 
not DAD or PWV). It is well recognised that patients 
with albuminuria have markedly elevated cardiovascular 
risk [13, 14] which may in part be reduced by RAAS inhi-
bition [15, 16]. Although only an observational inding 
we believe that ours is the irst study to show that aor-
tic stifness associated with diabetes can be reduced by 
medical intervention. A previous randomised study has 
shown that RAAS modulation with spironolactone can 
decrease aortic stifness in patients with chronic kidney 
disease [17]. Our indings suggest the same might be true 
in diabetes although larger randomised trials are needed 
to establish whether decreasing aortic stifness by RAAS 
inhibition leads to improved outcomes.
Recent trials of hypoglycaemic agents in type 2 dia-
betes have included patients with established CVD [31] 
or at risk of CVD [32] and have shown that it is possi-
ble to improve CVD outcomes in these patient groups. 
AAD measured by CMR has the potential to be used as 
a surrogate endpoint in future studies of hypoglycaemic 
agents to identify those with increased CVD risk who 
are most likely to demonstrate mortality beneit. Fur-
thermore AAD could easily be added to a scan protocol 
including comprehensive assessment of cardiac structure 
function and tissue characteristics.
Limitations
his was an observational non-randomised study and 
the interventional component needs to be repeated in a 
larger randomised study, although it can be argued that 
this is a strength as patient selection was limited and they 
were studied under real life, and not randomised con-
trolled trial, conditions.  9/19 patients with CVD events 
were asymptomatic with MI being detected on LGE 
CMR. However in patients with diabetes the mortal-
ity associated with unrecognised MI is signiicant and is 
comparable to those with clinically recognised MI [33, 
34]. he temporal resolution of the CMR PWV was at 
least 10 times lower than that achieved by tonometry 
and the lack of association between PWV and glycae-
mia or CVD events may relect a limitation of the tech-
nique used. here was a male preponderance in this 
cohort relecting the diferent cut-ofs for ACR, which 
may have inluenced our indings. he blood pressure 
measurement for AD calculation was performed periph-
erally which due to the pressure ampliication phenom-
enon could lead to overestimation of stifness, although 
the identical protocol was used for all subjects therefore 
minimising bias.
Conclusions
Ascending aortic distensibility measured by CMR is inde-
pendently associated with poor glycaemic control and 
adverse cardiovascular events. Furthermore, it appears to 
be reversible on treatment with RAAS inhibition. AAD 
is a promising marker of cardiovascular risk in asympto-
matic patients with type 2 diabetes and has potential use 
as a surrogate cardiovascular endpoint in studies of novel 
hypoglycaemic agents.
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